Treace Medical Concepts, Inc. (TMCI) Financial Statements
Treace Medical Concepts, Inc. (TMCI) reported trailing twelve-month revenue of $205.3M (down 4.0% year on year) and net income of -$59.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$25.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TMCITreace Medical Concepts, Inc.Follow TMCI — free
—
Price chart with a free account
- Market cap
- 277.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 94.4 | 141.8 | 187.1 | 209.4 | 212.7 | 205.3 | |
| Gross profit | 77.5 | 116.3 | 151.9 | 168.3 | 169.8 | 163.1 | |
| Research & development | 10.2 | 13.6 | 15.4 | 20.6 | 20.3 | 18.2 | |
| Operating income | -16.5 | -34.8 | -51.4 | -55.7 | -54.2 | -53.7 | |
| Pre-tax income | -20.6 | -42.8 | -49.5 | -55.7 | -59.0 | -59.5 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -20.6 | -42.8 | -49.5 | -55.7 | -59.0 | -59.5 | |
| Diluted EPS ($) | -0.43 | -0.77 | -0.81 | -0.90 | -0.93 | -0.92 | |
| Diluted shares (mn) | — | 55.3 | 60.9 | 62.1 | 63.3 | — |
USD millions · SEC XBRL
Treace Medical Concepts, Inc. — questions
- What is Treace Medical Concepts, Inc.'s revenue?
- $205.3M over the twelve months to 2026-06-30, down 4.0% year on year, from its 10-Q and 10-K filings.
- What is Treace Medical Concepts, Inc.'s net income?
- -$59.5M over the twelve months to 2026-06-30.
- What is Treace Medical Concepts, Inc.'s free cash flow?
- -$25.0M over the twelve months to 2026-06-30.
- What are Treace Medical Concepts, Inc.'s diluted earnings per share?
- $-0.92 over the twelve months to 2026-06-30.
Every figure on this page comes from Treace Medical Concepts, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.